SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.730
-0.090 (-2.36%)
Jul 13, 2026, 4:00 PM EDT - Market closed
SAB Biotherapeutics Market Cap
SAB Biotherapeutics has a market cap or net worth of $285.21 million as of July 13, 2026. Its market cap has increased by 1,624.45% in one year.
Market Cap
285.21M
Enterprise Value
183.99M
1-Year Change
1,624.45%
Ranking
Category
Stock Price
$3.73
Market Cap Chart
Since February 9, 2021, SAB Biotherapeutics's market cap has increased from $130.75M to $285.21M, an increase of 118.13%. That is a compound annual growth rate of 15.46%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 13, 2026 | 285.21M | 60.19% |
| Dec 31, 2025 | 178.05M | 408.46% |
| Dec 31, 2024 | 35.02M | -44.79% |
| Dec 29, 2023 | 63.43M | 113.36% |
| Dec 30, 2022 | 29.73M | -91.24% |
| Dec 31, 2021 | 339.54M | 159.68% |
| Feb 9, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| InflaRx | 303.42M |
| Galectin Therapeutics | 302.94M |
| Lineage Cell Therapeutics | 301.65M |
| Eledon Pharmaceuticals | 298.39M |
| Indaptus Therapeutics | 297.83M |
| Neumora Therapeutics | 296.45M |
| MacroGenics | 286.03M |
| Turn Therapeutics | 282.09M |